Changes in ADMA and TAFI levels after stenting in coronary artery disease             patients.
The aim of this study was to examine the contribution of asymmetric dimethylarginine             (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS) and a novel marker             of vascular endothelial dysfunction, and thrombin-activatable fibrinolysis inhibitor             (TAFI), a risk factor for venous thrombosis, to the predisposition of coronary             restenosis following stent implantation in coronary artery disease (CAD) patients.             Thirty-seven patients with CAD were recruited from the Kobry El Obba Military             Hospital, Cairo, Egypt. The patients were hospitalized for coronary angiography             and coronary stenting (CS). Overnight fasting blood samples were collected from             patients prior to CS and four months later for the determination of plasma ADMA             and TAFI levels. The patients underwent follow-up coronary angiography to reveal             in-stent restenosis. The results showed that plasma ADMA levels in CAD patients             were significantly higher than those reported for healthy subjects. ADMA levels             were significantly increased by 30% in CAD patients four months following CS.             CAD patients who developed in-stent restenosis had a 35% increase in ADMA levels             following CS. TAFI levels were not significantly changed after CS in CAD patients             or in any of the subgroups. In conclusion, ADMA, but not TAFI, is linked to the             predisposition of in-stent restenosis following CS.
Department of Pharmacology, Faculty of Pharmacy and Biotechnology,                     German University in Cairo, Cairo, Egypt.
Nouran M
NM
Khalifa
Mohamed Z
MZ
Gad
Alaa A
AA
Hataba
Laila G
LG
Mahran
D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood; D025901:Carboxypeptidase B2 / Q000097:blood*; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008875:Middle Aged; D012907:Smoking; D015607:Stents
C487735:dimethylarginine; D001120:Arginine; D025901:Carboxypeptidase B2